Xenon Pharmaceuticals Inc. (XENE)
NASDAQ
Xenon Pharmaceuticals Inc. Shareholder Equity 2012–2025
Xenon Pharmaceuticals Inc. annual shareholder equity history from 2013 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Xenon Pharmaceuticals Inc. shareholder equity as of December 31, 2025: 581.8M, a 22.94% decrease year-over-year.
- Xenon Pharmaceuticals Inc. shareholder equity for 2025 were 581.8M, a 22.94% decrease from 2024.
- Xenon Pharmaceuticals Inc. shareholder equity for 2024 were 754.9M, a 18.65% decrease from 2023.
- Xenon Pharmaceuticals Inc. shareholder equity for 2023 were 927.9M, a 28.61% increase from 2022.
- Xenon Pharmaceuticals Inc. shareholder equity for 2022 were 721.5M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Xenon Pharmaceuticals Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $582 |
| 2024 | $755 |
| 2023 | $928 |
| 2022 | $721 |
| 2021 | $550 |
| 2020 | $171 |
| 2019 | $92 |
| 2017 | $36 |
| 2016 | $64 |
| 2015 | $61 |
| 2014 | $73 |
| 2013 | $-78 |
Xenon Pharmaceuticals Inc. Shareholder Equity — FAQ
Xenon Pharmaceuticals Inc. (XENE) shareholder equity over the last 13 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see XENE's shareholder equity history?
The chart and table above show Xenon Pharmaceuticals Inc.'s shareholder equity by year and by quarter, including the growth rate.